The Investor
19 Nov 2026, 18:44
Zoetis Wins USDA License for 3-in-1 Poultry Vaccine
Zoetis (NYSE: ZTS) received a U.S. Department of Agriculture license for Poulvac Procerta HVT-ND-ILT, a new vector vaccine designed to protect chickens against Marek’s disease, Newcastle disease and infectious laryngotracheitis.
The 3-in-1 vaccine is labeled for use in healthy one-day-old chickens or 18- to 19-day-old embryonated eggs and is intended to give veterinarians and poultry producers greater flexibility when designing flock-health programs.
The product expands Zoetis’ existing poultry vaccine portfolio, which also includes solutions targeting infectious bursal disease, infectious bronchitis, Salmonella and E. coli. The company said Poulvac Procerta HVT-ND-ILT can also be incorporated into seasonal or rotational infectious laryngotracheitis vaccination strategies.
The USDA license strengthens Zoetis’ poultry-health offering by adding a broader combination vaccine to its U.S. portfolio. While the announcement does not include financial guidance, the approval expands the company’s addressable opportunity in commercial poultry disease prevention.
Zoetis (NYSE: ZTS) received a U.S. Department of Agriculture license for Poulvac Procerta HVT-ND-ILT, a new vector vaccine designed to protect chickens against Marek’s disease, Newcastle disease and infectious laryngotracheitis.
The 3-in-1 vaccine is labeled for use in healthy one-day-old chickens or 18- to 19-day-old embryonated eggs and is intended to give veterinarians and poultry producers greater flexibility when designing flock-health programs.
The product expands Zoetis’ existing poultry vaccine portfolio, which also includes solutions targeting infectious bursal disease, infectious bronchitis, Salmonella and E. coli. The company said Poulvac Procerta HVT-ND-ILT can also be incorporated into seasonal or rotational infectious laryngotracheitis vaccination strategies.
The USDA license strengthens Zoetis’ poultry-health offering by adding a broader combination vaccine to its U.S. portfolio. While the announcement does not include financial guidance, the approval expands the company’s addressable opportunity in commercial poultry disease prevention.